CluenexIonis Pharmaceuticals IONS
Ionis Pharmaceuticals scores weak on business quality (4.3 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Ionis Pharmaceuticals does
Ionis Pharmaceuticals discovers and develops RNA-targeted therapeutics, generating revenue through licensing fees, milestone payments, and commercialized drugs paid for by pharmaceutical partners and healthcare providers.
- What it does best
Ionis dominates RNA-targeted drug discovery, posting a gross margin of 98.1% compared to HALO at 82.4%. This technological edge stems from decades of pioneering antisense intellectual property that competitors cannot easily replicate.
- The main risk
Heavy cash burn threatens operations as net income sits at -$565M with free cash flow at -$560M, leaving the firm dependent on ongoing capital raises or milestone inflows to fund its extensive clinical pipeline.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin sits at -68.0% and return on equity is -110.9%, both ranking in the bottom decile of its sector. High research costs mean losses expand alongside revenue rather than improving with scale.
A narrow technological moat protects its proprietary antisense platform, locking in development partners. Sector percentiles show a top-decile gross margin rank of 98, though lack of profitability limits broader competitive insulation.
Revenue reached $874M, backed by a 34% revenue growth rate that places the firm in the top decile of its sector. This top-line expansion accelerates compared to historical multi-year revenue fluctuations.
Total debt of $2.3B outweighs equity significantly, while interest coverage of -31.6x means operating earnings fail to cover borrowing costs. Free cash flow remains deeply negative at -$560M, weakening the balance sheet.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
1 insider bought $1.1M on the open market.
Our sealed record on IONS
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Ionis Pharmaceuticals scores weak on the Cluenex quality check (4.3 of 10), measured against its own industry. Profitability is weak, moat fair, growth fast and financial health weak.
In the last 90 days of SEC Form 4 filings: 1 insider bought $1.1M on the open market.
Oct 27, 2026.
See IONS today
- Today's verdict on IONS, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Ionis Pharmaceuticals (IONS)”, https://cluenex.com/stocks/ions/, data as of Oct 10, 2026.